Samsung looks to deepen involvement in biotech/healthcare; Histogenics prices IPO below the range;

@FierceBiotech: Bayer tees up its new #hemophilia drug for an @US_FDA submission. More | Follow @FierceBiotech

@JohnCFierce: Busy biotechs bag $121M in VC cash. Article | Follow @JohnCFierce

@DamianFierce: Considering @GenzymeCorp's party for Cerdelga, how big was the Lemtrada cake? More | Follow @DamianFierce

> Korean conglomerate Samsung, which has invested heavily in biosimilars, says it expects to deepen its involvement in the biotech and healthcare field as it looks to improve revenue. Story

> The regenerative med company Histogenics has priced its IPO at $11, well below the $13 to $15 range it had set for itself. Story

Medical Device News

@FierceMedDev: Edison Nation and Mount Sinai team up for device innovation. More | Follow @FierceMedDev

@EmilyWFierce: Tax-inversion loophole likely to cost the government $2.2B in lost tax revenue next year. Story | Follow @EmilyWFierce

> Illumina and Sequenom lay prenatal diagnostic patent feud to rest. More

> New study supports effectiveness of 3-D breast cancer mammography. News

> Xeltis gets $34M to develop biodegradable heart valves and vessels. Article

Pharma News

@FiercePharma: IMS: Rebates, discounts could take an $80B bite out of U.S. drug spending through 2018. Story | Follow @FiercePharma

@CarlyHFierce: J&J looks for Xarelto boost in real-world cost data. Article | Follow @CarlyHFierce

> Pfizer believes a dose of confidence will help it sell biosimilars. More

> Will buyers go after Mylan once it inverts? Don't count on it, analyst says. Story

Drug Delivery News

> DBV's peanut allergy patch tests well, boosting its market value to almost $1B. Report

> Valerion teams up with Catalent to develop orphan drug delivery tech. News

> Recipharm purchases Flamel facility with delivery partnership. Story

> U.S. Army deploys a novel topical antiseptic to fight ebolavirus. Article

> NIH grants $20M to develop an intravaginal ring to prevent HIV. More

Diagnostics News

> Cepheid wins FDA nod for norovirus test. Report

> Germany's nanoPET partners with Boehringer Ingelheim for imaging Dx deal. News

> Philips gets FDA approval for spectral imaging system. Story

> Roche dives into prenatal Dx space with Ariosa purchase. Item

> U.K. and Wellcome Trust back trial of new, 15-minute Ebola test in West Africa. Article

Pharma Marketing News

> PhIII failure dashes Novartis' hopes of Gilenya label expansion. Report

> Reports: BMS whittles China sales operation by 1,000. More

> J&J looks for Xarelto boost in real-world cost data. Story

> Pfizer believes a dose of confidence will help it sell biosimilars. Link

> IMS: Rebates, discounts could take an $80B bite out of U.S. drug spending through 2018. Article

Suggested Articles

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.

The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.